GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (LIM:GILD) » Definitions » Cyclically Adjusted Price-to-FCF

Gilead Sciences (LIM:GILD) Cyclically Adjusted Price-to-FCF : 9.90 (As of Dec. 14, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Gilead Sciences Cyclically Adjusted Price-to-FCF?

As of today (2024-12-14), Gilead Sciences's current share price is $96.32. Gilead Sciences's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2024 was $9.73. Gilead Sciences's Cyclically Adjusted Price-to-FCF for today is 9.90.

The historical rank and industry rank for Gilead Sciences's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

LIM:GILD' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 6.45   Med: 10.65   Max: 58.94
Current: 9.32

During the past years, Gilead Sciences's highest Cyclically Adjusted Price-to-FCF was 58.94. The lowest was 6.45. And the median was 10.65.

LIM:GILD's Cyclically Adjusted Price-to-FCF is ranked better than
90.14% of 294 companies
in the Drug Manufacturers industry
Industry Median: 31.175 vs LIM:GILD: 9.32

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Gilead Sciences's adjusted free cash flow per share data for the three months ended in Sep. 2024 was $3.324. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is $9.73 for the trailing ten years ended in Sep. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Gilead Sciences Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Gilead Sciences's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Cyclically Adjusted Price-to-FCF Chart

Gilead Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.97 8.30 8.95 9.47 8.32

Gilead Sciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.75 8.32 7.34 7.00 8.51

Competitive Comparison of Gilead Sciences's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - General subindustry, Gilead Sciences's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gilead Sciences's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's Cyclically Adjusted Price-to-FCF falls into.



Gilead Sciences Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Gilead Sciences's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=96.32/9.73
=9.90

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gilead Sciences's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2024 is calculated as:

For example, Gilead Sciences's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=3.324/133.0289*133.0289
=3.324

Current CPI (Sep. 2024) = 133.0289.

Gilead Sciences Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201412 1.782 99.070 2.393
201503 3.554 99.621 4.746
201506 3.563 100.684 4.708
201509 2.535 100.392 3.359
201512 3.829 99.792 5.104
201603 2.800 100.470 3.707
201606 3.528 101.688 4.615
201609 3.133 101.861 4.092
201612 2.543 101.863 3.321
201703 2.127 102.862 2.751
201706 2.584 103.349 3.326
201709 1.945 104.136 2.485
201712 1.920 104.011 2.456
201803 1.559 105.290 1.970
201806 0.976 106.317 1.221
201809 1.565 106.507 1.955
201812 1.622 105.998 2.036
201903 1.044 107.251 1.295
201906 1.689 108.070 2.079
201909 1.930 108.329 2.370
201912 1.866 108.420 2.290
202003 0.996 108.902 1.217
202006 1.931 108.767 2.362
202009 1.661 109.815 2.012
202012 1.354 109.897 1.639
202103 1.937 111.754 2.306
202106 1.744 114.631 2.024
202109 2.468 115.734 2.837
202112 2.416 117.630 2.732
202203 1.262 121.301 1.384
202206 1.317 125.017 1.401
202209 2.146 125.227 2.280
202212 1.886 125.222 2.004
202303 1.297 127.348 1.355
202306 1.748 128.729 1.806
202309 1.299 129.860 1.331
202312 1.557 129.419 1.600
202403 1.695 131.776 1.711
202406 0.955 132.554 0.958
202409 3.324 133.029 3.324

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Gilead Sciences  (LIM:GILD) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Gilead Sciences Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Gilead Sciences Business Description

Address
333 Lakeside Drive, Foster, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).